Abstract:Upregulation of programmed death ligand 1 (PD-L1) helps tumor cells escape from immune surveillance, and therapeutic antibodies targeting PD-1/PD-L1 have shown better patient outcomes only in several types of malignancies. Recent studies suggest that the clinical efficacy of anti-PD-1/PD-L1 treatments is associated with PD-L1 levels; however, the underlying mechanism of high PD-L1 protein levels in cancers is not well defined. Here, we report that the deubiquitinase OTUB1 positively regulates PD-L1 stability and mediates cancer immune responses through the PD-1/PD-L1 axis. Mechanistically, we demonstrate that OTUB1 interacts with and removes K48-linked ubiquitin chains from the PD-L1 intracellular domain in a manner dependent on its deubiquitinase activity to hinder the degradation of PD-L1 through the ERAD pathway. Functionally, depletion of OTUB1 markedly decreases PD-L1 abundance, reduces PD-1 protein binding to the tumor cell surface, and causes increased tumor cell sensitivity to human peripheral blood mononuclear cells (PBMCs)-mediated cytotoxicity. Meanwhile, OTUB1 ablation-induced PD-L1 destabilization facilitates more CD8+ T cells infiltration and increases the level of IFN-γ in serum to enhance antitumor immunity in mice, and the tumor growth suppression by OTUB1 silencing could be reversed by PD-L1 overexpression. Furthermore, we observe a significant correlation between PD-L1 abundance and OTUB1 expression in human breast carcinoma. Our study reveals OTUB1 as a deubiquitinating enzyme that influences cancer immunosuppression via regulation of PD-L1 stability and may be a potential therapeutic target for cancer immunotherapy.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: **To reveal the mechanism by which the deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression by stabilizing the immune checkpoint protein PD - L1**. Specifically, the study aims to clarify how OTUB1 maintains the stability of PD - L1 by preventing the formation of K48 - linked polyubiquitin chains in the endoplasmic reticulum - associated degradation (ERAD) pathway, and to explore its potential targeting value in cancer immunotherapy. ### Analysis of the Core Problems in the Paper 1. **Background and Motivation** - The up - regulation of programmed death - ligand 1 (PD - L1) helps tumor cells escape immune surveillance, and therapeutic antibodies against PD - 1/PD - L1 show better patient prognosis in some types of malignancies. - Clinical studies indicate that the efficacy of anti - PD - 1/PD - L1 treatment is related to PD - L1 levels, but the specific regulatory mechanism of high PD - L1 protein levels in cancer has not been fully elucidated. 2. **Research Objectives** - To clarify how OTUB1 (a deubiquitinating enzyme) affects the cancer immune response by regulating the stability of PD - L1. - To explore whether OTUB1 prevents PD - L1 from being degraded through the ERAD pathway by removing K48 - linked polyubiquitin chains on PD - L1. - To analyze whether the regulation of PD - L1 stability by OTUB1 depends on its catalytic activity. - To evaluate the role of OTUB1 in different cancer cell lines and its potential as a target for cancer immunotherapy. 3. **Research Methods** - Use multiple experimental techniques, including Western blotting, co - immunoprecipitation (Co - IP), proximity ligation assay (PLA), in vivo and in vitro deubiquitination experiments, etc., to verify the interaction between OTUB1 and PD - L1 and their regulatory mechanisms. - Through gene knockdown and overexpression experiments, observe the specific effects of OTUB1 on PD - L1 expression and stability. - Use CRISPR/Cas9 gene - editing technology to construct OTUB1 - knockout cell lines to further confirm the function of OTUB1. - Conduct bioinformatics analysis to explore the expression correlation between OTUB1 and PD - L1 in human breast cancer. 4. **Main Findings** - OTUB1 maintains the stability of PD - L1 by directly binding to PD - L1 and removing its K48 - linked polyubiquitin chains, preventing PD - L1 from being degraded through the ERAD pathway. - The catalytic activity of OTUB1 is crucial for its regulation of PD - L1 stability. - The deletion of OTUB1 significantly reduces the abundance of PD - L1, increases the sensitivity of tumor cells to T - cell - mediated cytotoxicity, and enhances the anti - tumor immune response. - In a mouse model, the silencing of OTUB1 inhibits tumor growth, and this effect can be reversed by the overexpression of PD - L1. - Analysis of clinical samples shows that OTUB1 expression is positively correlated with PD - L1 abundance in human breast cancer. In conclusion, this study reveals that OTUB1, as a new deubiquitinating enzyme, plays an important role in cancer immunosuppression by regulating PD - L1 stability, providing a potential target for the development of new cancer immunotherapy methods.

Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1

O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation

Deubiquitinating enzyme OTUB1 in immunity and cancer: Good player or bad actor?

Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1

Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy

OTUB1-catalyzed deubiquitination of FOXM1 facilitates tumor progression and predicts a poor prognosis in ovarian cancer.

The deubiquitinase OTUD1 inhibits non‐small cell lung cancer progression by deubiquitinating and stabilizing KLF4

Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation

Deubiquitination and Stabilization of PD-L1 by USP21

ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy

Deubiquitinase OTUD6A Promotes Breast Cancer Progression by Increasing TopBP1 Stability and Rendering Tumor Cells Resistant to DNA-damaging Therapy.

The deubiquitinating enzyme OTUD1 antagonizes BH3-mimetic inhibitor induced cell death through regulating the stability of the MCL1 protein

The deubiquitinase Otub1 controls the activation of CD8+ T cells and NK cells by regulating IL-15-mediated priming.

The deubiquitinase OTUD1 enhances iron transport and potentiates host antitumor immunity

USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1

Target deubiquitinase OTUB1 as a therapeatic strategy for BLCA via β-catenin/necroptosis signal pathway

Deubiquitinase OTUD7B regulates cell proliferation in breast cancer

Overexpression of OTU domain-containing ubiquitin aldehyde-binding protein 1 exacerbates colorectal cancer malignancy by inhibiting protein degradation of β-Catenin via Ubiquitin-proteasome pathway

Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic target

OTUB1 inhibits breast cancer by non‐canonically stabilizing CCN6

Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7